At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 21, 2026 at 07:00 ET
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsCRP and other inflammatory biomarkers in obese participants with elevated inflammation. The company plans to initiate Phase 2 proof-of-concept trials in cardiovascular risk and diabetic macular edema by mid-2026, with data expected by end-2026 and mid-2027, respectively.
- BGE-102 achieved 85% median hsCRP reduction at 60 mg dose and 86% at 120 mg dose in participants with obesity and elevated inflammation
- 87% of participants on 60 mg dose achieved normalized hsCRP (<2 mg/L) by Day 21
- Drug was well tolerated with no serious adverse events or discontinuations
- Phase 2 cardiovascular risk trial planned for initiation in first half of 2026, with data by end of year
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access